156
Participants
Start Date
June 30, 2012
Primary Completion Date
June 30, 2014
Study Completion Date
August 31, 2014
AC607
AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
Vehicle Only
The dose will be calculated and recorded in the same way as for AC607.
Columbia University Medical Center, New York
Lankenau Medical Center, Wynnewood
MedStar Washington Hospital Center, Washington D.C.
Johns Hopkins University, Baltimore
University of Virginia Health System, Charlottesville
CAMC Clinical Trials Center, Charleston
Duke University Medical Center, Durham
University of Alabama at Birmingham, Birmingham
Ohio State University, Columbus
Henry Ford Hospital, Detroit
Mayo Clinic, Rochester
Northwestern University, Chicago
UTHealth, The University of Texas Health Science Center at Houston, Houston
University of California, San Diego, San Diego
University of Washington Medical Center, Seattle
Stanford Hospital and Clinics, Stanford
Maine Medical Center, Portland
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Rutgers Robert Wood Johnson Medical School, New Brunswick
Fletcher Allen Health Care - Renal Services, Burlington
Foothills Medical Centre, Calgary
University of Alberta Hospital, Edmonton
University of Manitoba - St. Boniface Hospital, Winnipeg
CDHA Queen Elizabeth II Health Sciences Centre, Halifax
McMaster - Hamilton General Hospital / TAARI, Hamilton
London Health Sciences Centre, University Hospital, London
St. Michael's Hospital, Toronto
Toronto General Hospital, Toronto
Montreal Heart Institute, Montreal
Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec
Lead Sponsor
AlloCure Inc.
INDUSTRY